Obeldesivir

Phase 3Small molecule

Gilead

Obeldesivir is one of 22 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

RSV InfectionTerminated

COVID-19Phase 3

Active, not recruiting

RSV InfectionPhase 2

Terminated

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Obeldesivir

Gilead

Phase 3

3 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Benadryl

PParkedale

Preclinical

1 6

SARS-COV-2 VACCINE

Moderna

Preclinical

2 7

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—8

Conventional

PPopulation Health Research Institute

Preclinical

1 9

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-193 trials

Study of Obeldesivir in Children and Adolescents With COVID-19

Terminated· Gilead logo

Gilead·Phase 2/3·NCT05996744·3 enrolled

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Terminated· Gilead logo

Gilead·Phase 3·NCT05603143·468 enrolled

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

Completed· Gilead logo

Gilead·Phase 3·NCT05715528·2,011 enrolled

Respiratory Syncytial Virus (RSV) Infection1 trial

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Terminated· Gilead logo

Gilead·Phase 2·NCT06784973·4 enrolled

Virus Diseases1 trial

Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

Withdrawn· Gilead logo

Gilead·Phase 2·NCT06682234

RSV Infection1 trial

A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Terminated· Gilead logo

Gilead·Phase 2·NCT06585150·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Obeldesivir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Obeldesivir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Obeldesivir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

Obeldesivir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-193 trials

Respiratory Syncytial Virus (RSV) Infection1 trial

Virus Diseases1 trial

RSV Infection1 trial

References

Drug Info

Quick Facts

Related News